Fig. 8.
SU5416- and SU6668-treated AML blast cells demonstrate increased expression of activated caspase-3.
AML blasts in medium containing 10% FBS (panel A: patient No. 1) or 0.1% FBS (panels B,C: patient No. 8) were pretreated with SU5416 for 1 hour or SU6668 for 24 hours prior to incubation with 100 ng/mL SCF; untreated samples were incubated with SCF only. At 24 hours, samples were stained with PE-conjugated antiactivated caspase-3 antibody and quantitated by fluorescence-activated cell sorter analysis. The asterisk indicates the apoptotic population.